Status:
RECRUITING
Registry BAsed Optimization Of Therapy in Heart Failure
Lead Sponsor:
Region Stockholm
Conditions:
Heart Failure
Eligibility:
All Genders
Phase:
NA
Brief Summary
Rationale. Although several pharmacological treatments, namely renin-angiotensin-system inhibitors, sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists and sodium-glucose cotra...
Eligibility Criteria
Inclusion
- Registration in SwedeHF with an index date after January 1st 2023 for the screening arm. For controls, hospital access after January 1st 2023.
- HF duration \>6 months to ensure that patients had time to go through the treatment optimization process as recommended by the guidelines.
- HF with reduced EF (HFrEF) defined as categorical or continuous EF ≤40%
- Capable of giving signed informed consent (for the screening arm)
Exclusion
- Under optimization of HF therapy
- In judgment of the investigator unlikely to understand or comply with study procedures
- Control population is sex and age matched with the SwedeHF screening arm (1:1)
Key Trial Info
Start Date :
May 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT07154758
Start Date
May 1 2024
End Date
June 30 2026
Last Update
September 4 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Sahlgrenska Universitetssjukhuset
Gothenburg, Sweden
2
Hemse vårdcentral
Hemse, Sweden
3
Länssjukhuset Ryhov
Jönköping, Sweden
4
Karolinska University Hospital
Stockholm, Sweden